[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.225.194.144. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 2004

Evaluating Pharmacogenetic Tests: A Case Example

Author Affiliations

From the Department of Pediatrics (Drs Freund, Gregory, and Wright Clayton), the Center for Genetics and Health Policy (Drs Freund and Wright Clayton), and the School of Law (Dr Wright Clayton), Vanderbilt University, Nashville, Tenn.

Arch Pediatr Adolesc Med. 2004;158(3):276-279. doi:10.1001/archpedi.158.3.276
Abstract

Work in human genetics is revealing genes that affect the safe and effective use of pharmaceuticals. Primary care physicians are already receiving advertisements for tests for these variations that emphasize the value of learning about their patients' susceptibility to adverse reactions in order to avoid them. We propose a strategy for the critical evaluation of such offers to ensure the optimal use of these tests.

×